{"entity":{"id":"nct06581406","kind":"trial","name":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P","aka":[],"tldr":"A phase 2/3 trial of Ipilimumab, Nivolumab in melanoma and uveal melanoma, run by Replimune, Inc., now recruiting.","summary":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma is a phase 2/3 interventional study registered as NCT06581406 by Replimune, Inc., with 280 participants planned, started 2024-12-17 and due to reach its primary completion in 2030-01. Interventions recorded: RP2, Ipilimumab, Nivolumab. Conditions listed: Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06581406","url":"https://clinicaltrials.gov/study/NCT06581406"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["ipilimumab","nivolumab"],"companies":["replimune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06581406","phase":"2/3","setting":"A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma","sponsor":"Replimune, Inc.","enrolled":280,"outcomes":[]},"route":"/trials/nct06581406/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"replimune","kind":"company","name":"Replimune","route":"/companies/replimune/"}]}}